ATE235235T1 - Arzneistoffverabreichungssystem auf basis von flüssigkristall-strukturen - Google Patents

Arzneistoffverabreichungssystem auf basis von flüssigkristall-strukturen

Info

Publication number
ATE235235T1
ATE235235T1 AT98956502T AT98956502T ATE235235T1 AT E235235 T1 ATE235235 T1 AT E235235T1 AT 98956502 T AT98956502 T AT 98956502T AT 98956502 T AT98956502 T AT 98956502T AT E235235 T1 ATE235235 T1 AT E235235T1
Authority
AT
Austria
Prior art keywords
drug
tpgs
liquid crystal
vitamin
dissolution
Prior art date
Application number
AT98956502T
Other languages
English (en)
Inventor
Garry L Myers
Original Assignee
Biovail Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovail Tech Ltd filed Critical Biovail Tech Ltd
Application granted granted Critical
Publication of ATE235235T1 publication Critical patent/ATE235235T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Liquid Crystal (AREA)
  • Liquid Crystal Substances (AREA)
AT98956502T 1997-11-21 1998-11-03 Arzneistoffverabreichungssystem auf basis von flüssigkristall-strukturen ATE235235T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/975,827 US5891845A (en) 1997-11-21 1997-11-21 Drug delivery systems utilizing liquid crystal structures
PCT/US1998/023359 WO1999026607A1 (en) 1997-11-21 1998-11-03 Drug delivery systems utilizing crystal structures

Publications (1)

Publication Number Publication Date
ATE235235T1 true ATE235235T1 (de) 2003-04-15

Family

ID=25523448

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98956502T ATE235235T1 (de) 1997-11-21 1998-11-03 Arzneistoffverabreichungssystem auf basis von flüssigkristall-strukturen

Country Status (9)

Country Link
US (1) US5891845A (de)
EP (1) EP1032373B1 (de)
JP (1) JP2001523705A (de)
AT (1) ATE235235T1 (de)
AU (1) AU1301199A (de)
CA (1) CA2309836C (de)
DE (1) DE69812690T2 (de)
ES (1) ES2196621T3 (de)
WO (1) WO1999026607A1 (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ328751A (en) * 1997-09-16 1999-01-28 Bernard Charles Sherman Solid medicament containing an anionic surfactant and cyclosporin
US6645192B2 (en) * 1998-09-30 2003-11-11 Ivy Animal Health, Inc. Pellet implant system for immediate and delayed release of antiparasitic drug
SK288117B6 (sk) * 1998-11-20 2013-09-03 Skyepharma Canada Inc. Rapidly dispersing solid dry therapeutic dosage form
EP1154759B1 (de) 1998-12-30 2008-08-13 Dexcel Ltd. Dispergierbares konzentrat zur verabreichung von cyclosporin
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
CA2397871A1 (en) * 2000-01-20 2001-07-26 Supratek Pharma Inc. Novel podophyllotoxin compositions
IL141438A0 (en) * 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
US7923469B2 (en) * 2001-04-30 2011-04-12 Allergen, Inc. Compositions including vitamin-based surfactants and methods for using same
GB0114532D0 (en) * 2001-06-14 2001-08-08 Jagotec Ag Novel compositions
GB0119480D0 (en) * 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US8663687B2 (en) * 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
HRP20040354B1 (en) * 2001-10-19 2012-10-31 Isotechnika Inc. Novel cyclosporin analog microemulsion preconcentrates
US7101576B2 (en) 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
AU2002350719A1 (en) 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
ATE411010T1 (de) * 2002-12-13 2008-10-15 Jagotec Ag Topische nanopartikel-spironolacton-formulierung
US20070249537A1 (en) * 2003-01-23 2007-10-25 Supernus Pharmaceuticals, Inc. Absorption enhancing agents
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
CN1889931A (zh) * 2003-12-04 2007-01-03 辉瑞产品公司 利用挤压器制备优选含泊洛沙姆和甘油酯的多重粒子阿奇霉素组合物的喷雾－冻凝方法
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
EP1694304A2 (de) * 2003-12-04 2006-08-30 Pfizer Products Inc. Multiteilchenförmige dosierformen von azithromycin durch verfahren auf flüssigkeitsbasis
BRPI0416534A (pt) * 2003-12-04 2007-01-09 Pfizer Prod Inc composições multiparticuladas com estabilidade melhorada
CA2549225A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
ATE399536T1 (de) * 2003-12-04 2008-07-15 Pfizer Prod Inc Verfahren zur herstellung von pharmazeutischen multiteilchenförmigen produkten
US7846940B2 (en) * 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
US8003122B2 (en) * 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US20050277584A1 (en) * 2004-06-09 2005-12-15 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
KR100623013B1 (ko) * 2004-09-04 2006-09-19 김영대 나노에멀션, 그의 용도 및 제조방법
ATE533473T1 (de) * 2004-09-24 2011-12-15 Boehringer Ingelheim Pharma Neue klasse von surfuctantähnlichen materialien mit vitamin-e-tpgs und wasserlöslichem polymer
US20060088591A1 (en) * 2004-10-22 2006-04-27 Jinghua Yuan Tablets from a poorly compressible substance
US20060188543A1 (en) * 2005-01-31 2006-08-24 Si-Shen Feng Nanoparticle coating for drug delivery
US20060240051A1 (en) * 2005-04-26 2006-10-26 Singleton Andy H Eutectic blends containing a water soluble vitamin derivative
WO2007056424A2 (en) * 2005-11-07 2007-05-18 Penwest Pharmaceuticals, Co. Controlled-release emulsion compositions
US20070167422A1 (en) * 2006-01-18 2007-07-19 Yu Kwok S Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
DE102006021016A1 (de) * 2006-05-05 2007-11-15 Dürschinger, Günter Chemisch aktivierbare Kapsel für die Durchgangsprüfung und Behandlung des Darm-Trakts
US20100016449A1 (en) * 2006-12-21 2010-01-21 Boehringer Ingelheim International Gmbh Formulations with Improved Bioavailability
EP2079456B1 (de) 2007-04-04 2012-12-05 Sigmoid Pharma Limited Pharmazeutische cyclosporin-zusammensetzungen
BRPI0701904A2 (pt) * 2007-04-27 2008-12-09 Libbs Farmaceutica Ltda forma farmacÊutica de liberaÇço controlada de princÍpios ativos com solubilidade dependente do baixo ph do meio e processo para preparar a forma farmacÊutica
EP2200613B1 (de) 2007-09-21 2018-09-05 The Johns Hopkins University Phenazin-derivate und ihre verwendungen
EP2257220B1 (de) * 2008-03-13 2017-06-14 Liebel-Flarsheim Company LLC Fussbetätigte multifunktionssteuerung für bildgebungssystem
SA109300195B1 (ar) 2008-03-28 2013-04-20 Astrazeneca Ab تركيبة صيدلانية جديدة مضادة للسرطان
US8420110B2 (en) * 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US8409601B2 (en) * 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
CN102125693A (zh) * 2011-01-25 2011-07-20 福建科瑞药业有限公司 一种盐酸噻加宾药物组合物及其制备方法
ITRM20120331A1 (it) 2012-07-12 2014-01-13 Guidotti & C Spa Labor Composizioni pediatriche orali liquide contenenti nepadutant.
US9789063B2 (en) * 2012-09-27 2017-10-17 Basf Se Storage-stable dust-free homogeneous particulate formulation
US9744240B2 (en) * 2012-09-27 2017-08-29 Basf Se Storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin E-derivative and at least one hydrophilic polymer
GB201222455D0 (en) * 2012-12-13 2013-01-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontaldisease
HUP1300647A2 (hu) * 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Ciklosporin A és származékainak komplexei, elõállításuk és gyógyszerészeti kompozícióik
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
KR20230137362A (ko) 2016-05-05 2023-10-04 어퀘스티브 테라퓨틱스, 아이엔씨. 강화된 전달 에프네프린 조성물
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
CN108295043B (zh) * 2018-03-16 2020-02-11 武汉百纳礼康生物制药有限公司 一种治疗胃溃疡的液晶凝胶纳米粒冻干粉胶囊剂及其制备方法
AU2019308326B2 (en) 2018-07-20 2025-07-31 Lipocine Inc. Liver disease
WO2022195545A1 (en) * 2021-03-18 2022-09-22 Novartis Ag Novel pharmaceutical formulations
EP4422607A4 (de) 2021-10-25 2025-09-03 Aquestive Therapeutics Inc Orale und nasale zusammensetzungen und behandlungsverfahren

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3867521A (en) * 1970-08-26 1975-02-18 Scherer Corp R P Method for absorption of drugs
DE3639073A1 (de) * 1986-11-14 1988-05-26 Klinge Co Chem Pharm Fab Feste arzneizubereitungen und verfahren zu ihrer herstellung
GB8630273D0 (en) * 1986-12-18 1987-01-28 Til Medical Ltd Pharmaceutical delivery systems
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
HU208491B (en) * 1990-11-27 1993-11-29 Gyogyszerkutato Intezet Process for producing oral pharmaceutical composition containing cyclosporin
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
HU215966B (hu) * 1994-11-21 1999-07-28 BIOGAL Gyógyszergyár Rt. Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum
WO1996036316A1 (en) * 1995-05-19 1996-11-21 Abbott Laboratories Self-emulsifying formulations of lipophilic drugs
MY126358A (en) * 1996-03-22 2006-09-29 Glaxo Group Ltd Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs
JP2001523221A (ja) * 1996-09-01 2001-11-20 ファーモス コーポレイション 親油性物質の促進された生物学的利用能のための固形共沈物

Also Published As

Publication number Publication date
DE69812690D1 (de) 2003-04-30
ES2196621T3 (es) 2003-12-16
EP1032373A1 (de) 2000-09-06
AU1301199A (en) 1999-06-15
CA2309836A1 (en) 1999-06-03
JP2001523705A (ja) 2001-11-27
EP1032373B1 (de) 2003-03-26
WO1999026607A1 (en) 1999-06-03
DE69812690T2 (de) 2004-01-22
CA2309836C (en) 2006-06-13
US5891845A (en) 1999-04-06

Similar Documents

Publication Publication Date Title
ATE235235T1 (de) Arzneistoffverabreichungssystem auf basis von flüssigkristall-strukturen
KR920700620A (ko) 서방성 경구 제형
DE69322077D1 (de) Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
IT1246382B (it) Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
DK1180020T3 (da) Poröse lægemiddelmatrixer og fremgangsmåder til fremstilling deraf
PE20001058A1 (es) Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial
MX172551B (es) Metodo y aparato para preparar una solucion de inyeccion
IT1201136B (it) Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
CY1108863T1 (el) Φαρμακευτικο σκευασμα εκτεταμενης απελευθερωσης ανεξαρτητης απο το ρη
IE882898L (en) Solubility modulated drug delivery device
AR057462A1 (es) Dispositivos de administracion transdermica de drogas que contienen drospirenona y metodos de administracion de la misma
CY1105026T1 (el) Συστημα χορηγησεως φαρμακου : συνθεση δια λιπο-διαλυτα φαρμακα
Chaus et al. Self-emulsifying drug delivery system: A review
ATE204163T1 (de) Verkapselter arzneistoff
PE20070377A1 (es) Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
HUP0104476A2 (hu) Hidroxi-propil-mutil-cellulóz kapszulákban formázott gyógyszerkészítmények
EA200000552A1 (ru) Готовые препаративные формы, содержащие растворенный пароксетин
EE03954B1 (et) Toimeaine pärsitud vabanemisega karbamasepiini ravimvormi valmistamise meetod
DK1144420T3 (da) Sulfaterede phosphatidylinositoler, fremgangsmåde til fremstilling heraf og anvendelser heraf
JP6184656B1 (ja) 胃腸管粘膜保護組成物
WO2000016784A1 (en) Oral drug delivery system for enhancing the bioavailability of activated glycyrrhetin
KR970069035A (ko) 새로운 진경제와 소염제의 합성 및 제조방법
KR20010072412A (ko) 경피 투여용 아스피린
US20170202786A1 (en) Novel pulsatile drug delivery system
Veski Use of Hard Gelatin Capsules and Sodium Alginates in Peroral Prolonged-release Formulations

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties